QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs ALT 803 (Primary) ; BCG
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms QUILT-3.032
- Sponsors Altor BioScience Corporation
- 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
- 05 Jun 2017 Planned End Date changed from 1 Aug 2020 to 1 Sep 2020.
- 05 Jun 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.